Can we accurately predict the development of rheumatoid arthritis in the preclinical phase?
Open Access
- 7 October 2003
- journal article
- editorial
- Published by Wiley in Arthritis & Rheumatism
- Vol. 48 (10) , 2701-2705
- https://doi.org/10.1002/art.11224
Abstract
No abstract availableFunding Information
- NIH (1-U19-AI-50864)
- Arthritis Foundation/American College of Rheumatology Research and Education Foundation
This publication has 39 references indexed in Scilit:
- Identification of Children with Early Onset and High Incidence of Anti-islet AutoantibodiesClinical Immunology, 2002
- Update on Major Trials for the Prevention of Type I Diabetes Mellitus: The American Diabetes Prevention Trial (DPT-1) and the European Nicotinamide Diabetes Intervention Trial (ENDIT)Journal of Pediatric Endocrinology and Metabolism, 2001
- Mortality in a cohort of Norwegian patients with rheumatoid arthritis followed from 1977 to 1992Scandinavian Journal of Rheumatology, 2000
- Progression to diabetes in relatives with islet autoantibodies. Is it inevitable?Diabetes Care, 1999
- Diagnosis and Treatment of Pre–Insulin Dependent DiabetesAnnual Review of Medicine, 1998
- Prophylactic insulin treatment in relatives at high risk for type 1 diabetesDiabetes/Metabolism Research and Reviews, 1993
- Characterisation of the rat oesophagus epithelium antigens defined by the so-called ‘antikeratin antibodies’, specific for rheumatoid arthritis.Annals of the Rheumatic Diseases, 1993
- The cytokeratin filament-aggregating protein filaggrin is the target of the so-called "antikeratin antibodies," autoantibodies specific for rheumatoid arthritis.Journal of Clinical Investigation, 1993
- The rheumatoid factor: An analysis of clinical utilityThe American Journal of Medicine, 1991
- The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritisArthritis & Rheumatism, 1988